Anti-VEGFA Magnetic Beads-IP Kit Product Components
| Components | Storage |
| Anti-VEGFA Magnetic Beads1,3 | 2-8℃ for 12 months |
| NP40 Cell Lysis Buffer2 | -20℃ for 12 months |
| 5×TBST（pH7.4） | |
| 1×TBST（pH7.4） | |
| ddH2O | |
| CD166 Positive Cell Lysate | -20℃ for 12 months |
| Alkaline Elution Buffer | 2-8℃ for 12 months |
| Acidity Elution Buffer | 2-8℃ for 12 months |
| Neutralization Buffer | 2-8℃ for 12 months |
[1] The IP KIT contains anti-VEGFA magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).
[2] Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.
[3] Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.
Anti-VEGFA Magnetic Beads-IP Kit Product Description
The Anti-VEGFA magnetic Beads, conjugated with Anti-VEGFA antibody, are used for immuneprecipitation (IP) of VEGFA proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing VEGFA proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound VEGFA proteins are dissociated from the magnetic beads using an elution buffer. Anti-VEGFA Magnetic Beads-IP Kit Antibody Information
Immunogen
A synthetic peptide corresponding to the center region of the human VEGFA
Species Reactivity
human VEGFA
Source
Polyclonal Human Rabbit IgG
Preparation
Produced in rabbits immunized with A synthetic peptide corresponding to the center region of the human VEGFA , and purified by antigen affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification
Anti-VEGFA Magnetic Beads Immunoprecipitation (IP) Kit Alternative Names
Anti-MVCD1ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-VEGFALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-VEGF165ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-VPFALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit
VEGFA Background Information
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.
Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy Full Name
vascular endothelial growth factor A
References
Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835. Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97. Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8. Hamdollah Zadeh MA, et al. (2008) VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 15(7): 605-14. Eisenach PA, et al. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 123(Pt 23):4182-4193. Claesson-Welsh L (2010) Gremlin: vexing VEGF receptor agonist. Blood. 116(18):3386-7.
新浪微博
腾讯微博
QQ空间
客服
